Par Pharmaceutical Companies, Inc, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets, announced that it will commence shipment of 12.5mg and 25mg meclizine HCl tablets immediately. At this time, Par believes it is the exclusive supplier of the AB-rated generic product.
Par marketed meclizine prior to an explosion at the facility of its API supplier in February 2008. Par has since qualified a new API source and received the appropriate approval of its supplemental new drug application to manufacture and market meclizine HCl utilizing its new API supplier.
Meclizine is an oral antiemetic indicated for the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. It is contraindicated in individuals who have shown a previous hypersensitivity to it.
source: www.pharmabiz.com
No comments:
Post a Comment